DeRubertis F R, Craven P A
Metabolism. 1976 Dec;25(12):1611-25. doi: 10.1016/0026-0495(76)90114-1.
There is evidence than adenosine 3',5'-monophosphate (cAMP) and guanosine 3',5'-monophosphate (cGMP) may have antagonistic actions on cell growth, with cAMP inhibiting and cGMP stimulating this process. However, reductions in cAMP and increases in cGMP are not charactersitic of all neoplastic tissues. Thus, benign and malignant tissues from hepatoma-bearing rats exposed to the hepatic carcinogen DL-ethionine have elevated rather than depressed cAMP, compared to control liver, and parenteral administration of this drug increases hepatic cAMP within hours. In the present study, the effects of ethionine ingestion on the hepatic content and metabolism of both cAMP and cGMP were examined sequentially in rats at 2 and then 6 wk intervals, from the initiation of drug administration until the development of hepatomas. After 2 wk, cAMP content of quick-frozen liver from rats receiving ethionine (E) was significantly increased (826 +/- 91 pmole/g wet weight) above that of liver from pair-fed controls (C, 415 +/- 44), whether calculated by tissue wet weight, protein, or DNA content. In benign tissue from E, higher cAMP was still evident after in vitro incubations of slices with 2 mM 1-methyl-3-iso-butylxanthine (MIX) and was associated with enhanced adenylate cyclase and unchanged high or low Km cAMP-phosphodiesterase activities. These findings are compatible with accelerated cAMP generation in liver from E. Protein kinase activity ratios were significantly increased in frozen liver from E (0.52 +/- 0.04 versus 0.36 +/- 0.03 in C), and the percent glycogen synthetase in the I form was clearly reduced (19% +/- 2% in E versus 47% +/- 5% in c). incubation of hepatic slices from E or C with MIX and/or 10 muM glucagon further increased cAMP and protein kinase activity ratios, data which imply higher effective, as well as total, cellular cAMP in E. Changes in cAMP metabolism and action observed at 2 wk persisted throughout the 38-wk period of drug ingestion. Adenylate cyclase activity, cAMP content, and protein kinase activity ratios of ethionine-induced hepatomas exceeded those of both the surrounding liver from tumor-bearing rats and that of control liver, but alterations in these parameters were qualitatively similar in both tissues from E. By contrast, while cGMP in quick-frozen surrounding liver from tumor-bearing rats (36 +/- 4 pmole/g wet weight) did not differ from that of control liver (30 +/- 3), cGMP in the hepatomas was increased. This change was evident in both frozen tumor (89 +/- 10) and in tumor slices incubated in vitro with MIX (C, 90 +/- 11; surrounding liver, 85 +/- 10; hepatoma 231 +/- 29). These results indicate that malignant conversion can occur in liver with a sustained elevation of both total and effective cAMP during the premalignant phase. The increase in cGMP detected in ethionine-induced hepatomas could also be a key determinant of malignant transformation in the model, although premalignant changes in cGMP were not apparent.
有证据表明,3',5'-环磷酸腺苷(cAMP)和3',5'-环磷酸鸟苷(cGMP)可能对细胞生长具有拮抗作用,其中cAMP抑制而cGMP刺激这一过程。然而,cAMP降低和cGMP升高并非所有肿瘤组织的特征。因此,与对照肝脏相比,暴露于肝致癌物DL-乙硫氨酸的荷肝癌大鼠的良性和恶性组织中cAMP升高而非降低,并且肠胃外给予该药物数小时内即可增加肝脏中的cAMP。在本研究中,从给药开始直到肝癌发生,以2周和6周的间隔依次检查乙硫氨酸摄入对大鼠肝脏中cAMP和cGMP含量及代谢的影响。2周后,无论按组织湿重、蛋白质还是DNA含量计算,接受乙硫氨酸(E)的大鼠速冻肝脏中的cAMP含量(826±91皮摩尔/克湿重)均显著高于配对喂养对照(C,415±44)的肝脏。在E组的良性组织中,用2mM 1-甲基-3-异丁基黄嘌呤(MIX)体外孵育切片后,较高的cAMP仍然明显,并且与腺苷酸环化酶增强以及高或低Km cAMP磷酸二酯酶活性不变有关。这些发现与E组肝脏中cAMP生成加速一致。E组速冻肝脏中的蛋白激酶活性比率显著增加(0.52±0.04,而C组为0.36±0.03),并且I型糖原合成酶的百分比明显降低(E组为19%±2%,而C组为47%±5%)。用MIX和/或10μM胰高血糖素孵育E组或C组的肝切片可进一步增加cAMP和蛋白激酶活性比率,这些数据表明E组细胞内有效cAMP以及总cAMP均较高。在2周时观察到的cAMP代谢和作用变化在38周的药物摄入期间持续存在。乙硫氨酸诱导的肝癌的腺苷酸环化酶活性、cAMP含量和蛋白激酶活性比率超过荷瘤大鼠的周围肝脏和对照肝脏,但E组两种组织中这些参数的变化在性质上相似。相比之下,虽然荷瘤大鼠速冻周围肝脏中的cGMP(36±4皮摩尔/克湿重)与对照肝脏(30±3)无差异,但肝癌中的cGMP增加。这种变化在冷冻肿瘤(89±10)以及用MIX体外孵育的肿瘤切片中均很明显(C组,90±11;周围肝脏,85±10;肝癌,231±29)。这些结果表明,在癌前阶段肝脏中总cAMP和有效cAMP持续升高时可发生恶性转化。在乙硫氨酸诱导的肝癌中检测到的cGMP增加也可能是该模型中恶性转化的关键决定因素,尽管癌前cGMP变化不明显。